Esperion Therapeutics to Acquire Corstasis, Expanding Cardiovascular Portfolio

Esperion Therapeutics (NASDAQ: ESPR) has announced a definitive agreement to acquire Corstasis Therapeutics, adding Enbumyst™ bumetanide nasal spray, the first and only FDA-approved intranasal loop diuretic, to its growing cardiovascular franchise.

The transaction includes $75 million in upfront cash, with up to $180 million in potential milestone payments, plus low double-digit royalties on future sales. The deal is expected to close in the second quarter of 2026, subject to customary approvals.

Strategic Expansion in Cardiovascular Therapeutics

Enbumyst received FDA approval in September 2025 for the treatment of edema associated with congestive heart failure (CHF) as well as edema linked to hepatic and renal disease in adults.

The therapy offers a differentiated outpatient treatment option designed to help manage fluid overload without requiring intravenous administration. This could support broader adoption in non-hospital settings, potentially improving patient convenience and reducing system burden.

For Esperion, the acquisition diversifies revenue beyond its LDL-cholesterol lowering products, including NEXLETOL® and NEXLIZET®, strengthening its position in cardiovascular care.

Why This Matters for ESPR Investors

The acquisition provides several potential benefits:

• Portfolio diversification beyond lipid management
• Immediate access to an FDA-approved commercial product
• Leverage of Esperion’s existing cardiovascular sales infrastructure
• Expansion into the heart failure and edema treatment market

Heart failure and fluid management represent a significant and growing therapeutic category, driven by aging populations and rising cardiovascular disease prevalence.

If successfully integrated, Enbumyst could add incremental revenue while enhancing Esperion’s commercial scale.

Financial and Execution Considerations

While the upfront payment is meaningful for a company of Esperion’s size, the milestone-based structure aligns a portion of the transaction value with future performance.

Investors should monitor:

• Commercial launch execution and prescription uptake
• Revenue contribution timing
• Gross margin profile
• Cash position and balance sheet impact
• Integration efficiency

As with any acquisition, execution risk will determine long-term value creation.

Bottom Line

The acquisition of Corstasis positions Esperion Therapeutics to expand beyond cholesterol management into a broader cardiovascular platform. By adding Enbumyst, an FDA-approved nasal diuretic for edema associated with heart failure, Esperion strengthens its commercial portfolio and growth narrative.